Recent and Future Drugs for the Treatment of Obesity

Gaal, Luc F. Van; Mertens, Ilse; Leeuw, Ivo H. De

doi:10.1002/0470846739.ch31

Cited by 2 publications

(5 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On average, a weight loss of 5 -15% can be expected over a period of approximately 3-6 months on the available prescription drugs 82 . Patients losing 2 kg by 1 month, or 5% of initial body weight by 12 weeks, should be encouraged to remain on lifelong therapy.…”

Section: Pharmacotherapymentioning

confidence: 99%

“…It is speculated that 19% of the obese patient population displays the characteristics of psychological readiness for intense treatment strategies, including pharmacotherapy. Drugs previously used in the management of obesity had addictive potential and serious sideeffects, such as pulmonary hypertension and valvular heart disease 82 , and have been withdrawn. Weight loss as well as improved health have been reported after treatment with sibutramine, a satiety enhancer 83 .…”

Section: Pharmacotherapymentioning

confidence: 99%

“…The use of drug therapy should be aimed at long-term weight management to reduce the need for other drugs that are often prescribed for the complications of obesity such as analgesics, lipid-lowering, antihypertensive and oral hypoglycaemic drugs. On average, a weight loss of 5 -15% can be expected over a period of approximately 3-6 months on the available prescription drugs 82 . Patients losing 2 kg by 1 month, or 5% of initial body weight by 12 weeks, should be encouraged to remain on lifelong therapy.…”

Section: Pharmacotherapymentioning

confidence: 99%

“…Two large prospective studies have shown remarkable longterm success of obesity management with sibutramine 83 and orlistat 84 . Studies evaluating the effect of growth hormone replacement 82 and rimonabant 85 75,76 composition have illustrated a potential for drug treatment.…”

Section: Pharmacotherapymentioning

confidence: 99%

See 3 more Smart Citations

Obesity in South Africa: challenges for government and health professionals

Kruger

Puoane

Senekal

et al. 2005

Public Health Nutr.

162

161

View full text Add to dashboard Cite

Objectives: To review data on the prevalence, causes and health consequences of obesity in South Africa and propose interventions to prevent and treat obesity and related outcomes. Methods: Data from existing literature were reviewed with an emphasis on changing eating and activity patterns, cultural factors, perceptions and beliefs, urbanisation and globalisation. Results of studies on the health consequences of obesity in South Africans are also reviewed. Results: Shifts in dietary intakes and activity patterns to higher fat intakes and lower physical activity are contributing to a higher prevalence of obesity. Few overweight black women view themselves as overweight, and some associate thinness with HIV/AIDS. Glucose and lipid toxicity, associated with insulin resistance, play roles in the pathogenesis of the co-morbid diseases of obesity. Elevated free fatty acids in the black population predispose obese black patients to type 2 diabetes. Conclusion and recommendations: Obesity prevention and treatment should be based on education, behaviour change, political support, intersectoral collaboration and community participation, local actions, wide inclusion of the population, adequately resourced programmes, infiltration of existing initiatives, evidence-based planning, and proper monitoring and evaluation. Interventions should have the following components: reasonable weight goals, healthful eating, physical activity and behavioural change. Genes and mutations affecting susceptibility to the development of co-morbidities of obesity and vulnerable periods of life for the development of obesity should be prioritised. Prevention should be managed in community services, identification of high-risk patients in primary healthcare services and treatment of co-morbid diseases in hospital services.

show abstract

Section: Pharmacotherapymentioning

confidence: 99%

Section: Pharmacotherapymentioning

confidence: 99%

Section: Pharmacotherapymentioning

confidence: 99%

Section: Pharmacotherapymentioning

confidence: 99%

See 2 more Smart Citations

Obesity in South Africa: challenges for government and health professionals

Kruger

Puoane

Senekal

et al. 2005

Public Health Nutr.

162

161

View full text Add to dashboard Cite

show abstract

“…We have a history of 6 months of exposure to sibutramine just before symptom onset. Fenfluramine and dexfenfluramin, anorectic drugs, which act through different but somewhat similar ways, were drawn from the market because of some valvular abnormalities and increased risk of primary pulmonary hypertension (PPH) [2]. It was reported that fenfluramine and its derivatives, after an exposure of 3 months or more increased the risk of having PPH by 23 times [3].…”

Section: Discussionmentioning

confidence: 99%

Sibutramine: possible cause of a reversible cardiomyopathy

Sayin

Güldal

2005

International Journal of Cardiology

View full text Add to dashboard Cite

Recent and Future Drugs for the Treatment of Obesity

Cited by 2 publications

References 122 publications

Obesity in South Africa: challenges for government and health professionals

Obesity in South Africa: challenges for government and health professionals

Sibutramine: possible cause of a reversible cardiomyopathy

Contact Info

Product

Resources

About